Blazin, Lindsay J
Mayo Clinic
Division of Hematology/Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
Citations 2
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
Binkley, Michael S. , Flerlage, Jamie E. , Savage, Kerry J. , Akhtar, Saad , Steiner, Raphaël , Zhang, Xiaoyin , Dickinson, Michael , Major, Ajay , Hendrickson, Peter G. , Hopkins, David , Ng, Andrea K. , Casulo, Carla , Baron, Jonathan , Roberts, Kenneth B. , Alkendi, Jalila , Balogh, Alex, Torka, Pallawi , Specht, Lena , Silva, Ravi De , Pickard, Keir , Henry, M M , Smith, Christine M. , Brady, J.L. , Brennan, Bernadette , Сенченко, М. А. , Reeves, Marie, Terezakis, Stephanie , Fergusson, Paige, Hawkes, Eliza A. , Lee, Denise , Barraclough, Allison , Cheah, Chan Y. , Ku, Matthew , Mutsando, Howard , Gilbertson, Michael , Marconi, Tamara , Viiala, Nicholas , Hoppe, Richard T. , Borchmann, Peter , Fuchs, Michael , Hartmann, Sylvia , Eich, Hans Theodor, Skinnider, Brian, Milgrom, Sarah A. , Alomari, Mohammed H., Advani, Ranjana H. , Metzger, Monika L. , Wirth, Andrew, Smith, Sonali M. , Koenig, Julie L. , Sakthivel, Ku G., Gao, Sarah , Rahbi, Nasser Al, Sridhar, Akshay , Shah, Nimish , Osborne, Wendy , Chang, Isabela , Miall, Fiona , Mikhaeel, G., Penn, Anthony, Pepa, Roberta Della , Opat, Stephen , Tedjaseputra, Aditya , Palese, Monica , Kelly, Kara M. , Binkley, Michael Sargent , Major, Ajay , Hopkins, David , Ng, Andrea , Casulo, Carla , Baron, Jonathan , Roberts, Kenneth B , Al Kendi, Jalila , Ricardi, Umberto , Torka, Pallawi , Specht, Lena , De Silva, Ravindu , Pickard, Keir , Blazin, Lindsay J , Smith, Christine M , Brady, Jessica , Senchenko, Maria Anatolevna , Hoppe, Bradford S , Terezakis, Stephanie A , Hawkes, Eliza , Doo, Nicole Wong , Barraclough, Allison , Cheah, Chan Yoon , Ku, Matthew , Hamad, Nada , Gilbertson, Michael , Marconi, Tamara , Maurer, Matthew , Eichenauer, Dennis A , Hoppe, Richard T , Savage, Kerry J , Advani, Ranjana H , Opat, Stephen , Dickinson, Michael , Flerlage, Jamie E , Prica, Anca A. , Casulo, Carla , Blazin, Lindsay , Henry, Michael, Halperin, Daniel M. , Hoppe, Bradford S. , Talaulikar, Dipti , Picardi, Marco , Kirova, Youlia , Doo, Nicole Wong , Hamad, Nada , Maurer, Matthew J. , Eichenauer, Dennis A. , Hodgson, David C. , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, Mohammed, Collins, Graham P. , Tsang, Richard , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Plastaras, John Peter , Levis, Mario , Sridhar, Akshay, Volchkov, Egor Vasilevich , Northend, Michael , Salvaris, Ross , Shankar, Ananth , Natkunam, Yasodha
Journal of Clinical Oncology | March 26, 2024 | Volume: 42 | Issue: 19 | Pages: 2271-2280
PURPOSE Nodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for all stages of pediatric and adult patients with NLPHL. METHODS Thirty-eight institutions participated in the Global nLPHL One Working Group retrospective study of NLPHL cases from 1992 to 2021. We measured progression-free survival (PFS), overall survival (OS), transformation rate, and lymphoma-specific death rate. We performed uni- and multivariable (MVA) Cox regression stratified by management to select factors for the lymphocyte-predominant international prognostic score (LP-IPS) validated by five-fold cross-validation. RESULTS We identified 2,243 patients with a median age of 37 years (IQR, 23-51). The median follow-up was 6.3 years (IQR, 3.4-10.8). Most had stage I to II (72.9%) and few B symptoms (9.9%) or splenic involvement (5.4%). IAP was scored for 916 (40.8%). Frontline management included chemotherapy alone (32.4%), combined modality therapy (30.5%), radiotherapy alone (24.0%), observation after excision (4.6%), rituximab alone (4.0%), active surveillance (3.4%), and rituximab and radiotherapy (1.1%). The PFS, OS, transformation, and lymphoma-specific death rates at 10 years were 70.8%, 91.6%, 4.8%, and 3.3%, respectively. On MVA, IAPs were not associated with PFS or OS, but IAP E had higher risk of transformation (hazard ratio [HR], 1.81; P < .05). We developed the LP-IPS with 1 point each for age ≥45 years, stage III-IV, hemoglobin <10.5 g/dL, and splenic involvement. Increasing LP-IPS was significantly associated with worse PFS (HR, 1.52) and OS (HR, 2.31) and increased risk of lymphoma-specific death (HR, 2.63) and transformation (HR, 1.41). CONCLUSION In this comprehensive study of all ages of patients with NLPHL, we develop the LP-IPS to identify high-risk patients and inform upcoming prospective clinical trials evaluating de-escalation of therapy for patients with low LP-IPS scores (<2).
Pediatric Aggressive Mature B-Cell Lymphomas, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Barth, Matthew J. , Audino, Anthony , Blazin, Lindsay , Chung, Jong , Davies, Kimberly, Ding, Hilda, Ford, James B. , Galardy, Paul J. , Hanna, Rabi , Hayashi, Robert J. , Lee‐Miller, Cathy , Machnitz, Andrea Judit, Maloney, Kelly W. , Marks, Lianna J. , Martin, Paul L. , Pacheco, Martha, Reilly, Anne F. , Roshal, Mikhail , Song, Sophie X. , Weinstein, Joanna , Zarnegar‐Lumley, Sara , McMillian, Nicole R., Schonfeld, Ryan, Sundar, Hema, Blazin, Lindsay J , Xavier, Ana C , Armenian, Saro H. , Bloom, David E. , McCall, David C.
Journal of the National Comprehensive Cancer Network | November 9, 2022 | Volume: 20 | Issue: 11 | Pages: 1267-1275
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Aggressive Mature B-Cell Lymphomas include recommendations for the diagnosis and management of pediatric patients with primary mediastinal large B-cell lymphoma (PMBL) and sporadic variants of Burkitt lymphoma and diffuse large B-cell lymphoma. PMBL is now considered as a distinct entity arising from mature thymic B-cells accounting for 2% of mature B-cell lymphomas in children and adolescents. This discussion section includes the recommendations outlined in the NCCN Guidelines for the diagnosis and management of pediatric patients with PMBL.